GSK plans large study to see if shingles vaccine can prevent dementia

Data scientists combing national health records over the past several years noticed a pattern: people vaccinated against shingles showed lower rates of Alzheimer’s diagnosis than those who were not. The observation, drawn from population-level datasets rather than a controlled trial, prompted GSK to plan a large-scale study testing whether its shingles vaccine, Shingrix, can help prevent dementia, according to Endpoints News.

The proposed trial would move beyond retrospective correlation toward a prospective test of the hypothesis. Endpoints News reports the study is being organized to determine whether vaccinating against the shingles-causing virus has a direct protective effect on cognitive decline, or whether the earlier associations reflect other factors common to people who seek out vaccination.

The shingles vaccine targets varicella-zoster virus, the same pathogen responsible for chickenpox, which can reactivate later in life. Researchers have floated various explanations for a possible link to dementia risk, including effects on inflammation or on viral reactivation in the nervous system, though Endpoints News did not report a confirmed mechanism.

GSK’s planning of the study marks a shift from observational data toward direct testing. No results are yet available. The trial’s design, timeline, and endpoints were not detailed in the available reporting. Findings, if the study proceeds, would take years to materialize.